# GRIN3B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *GRIN3B* gene encodes the GluN3B subunit of the NMDA receptor, a critical modulator of glutamatergic and glycinergic neurotransmission, influencing synaptic plasticity and motor neuron survival.
- GluN3B subunits confer unique biophysical properties to NMDA receptors, including the formation of excitatory glycine-gated channels and reduced Mg²⁺ sensitivity, altering downstream Ca²⁺ signaling pathways.
- Pathogenic variants in *GRIN3B* are associated with a spectrum of neuropsychiatric conditions, including schizophrenia, Tourette syndrome, PTSD, and substance use disorders, as well as motor neuron disease and cognitive aging.
- *GRIN3B* expression is epigenetically regulated by DNA methylation and histone modifications at its promoter, and its expression is developmentally regulated, with peak levels during embryonic stages.
- Structural analysis reveals a modular protein architecture with distinct ATD, LBD, TMD, and CTD domains, where the CTD mediates interactions with scaffolding proteins like PSD-95 and SAP102, crucial for receptor localization and function.
- Pharmacogenomic investigations are exploring *GRIN3B* as a potential therapeutic target, with investigational compounds like CGP 78608 and PPDA showing selectivity for GluN3-containing receptors.

---

## Executive Summary & Key Metadata

The *GRIN3B* gene encodes the glutamate ionotropic receptor NMDA type subunit 3B (GluN3B), an integral modulatory component of the N-methyl-D-aspartate (NMDA) receptor complex. Unlike the canonical GluN1 and GluN2 subunits that form conventional excitatory glutamatergic channels, GluN3B confers unique biophysical properties, including the formation of unconventional excitatory glycine-gated receptors and the reduction of Mg²⁺ sensitivity when co-assembled with GluN1/GluN2 complexes. The gene has been implicated in a spectrum of neuropsychiatric conditions, including schizophrenia, Tourette syndrome, post-traumatic stress disorder (PTSD), and substance use disorders, as well as in motor neuron physiology and cognitive aging. This reference manual provides an exhaustive analysis of the genomic architecture, structural biology, signaling pathways, pathogenic mutations, pharmacogenomic relevance, and bioinformatic resources associated with *GRIN3B*.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | GRIN3B |
| **UniProt Accession** | O60391 |
| **Representative PDB ID** | true (structural models available via homology to GluN3A; experimental structures pending) |
| **Chromosomal Locus** | 19p13.3 |
| **Primary Molecular Function** | NMDA receptor subunit; modulates glutamatergic and glycinergic neurotransmission; regulates synaptic plasticity and motor neuron survival |
| **Disease & Pathology Associations** | Schizophrenia, Tourette syndrome, PTSD, heroin addiction, anorexia nervosa, cognitive aging, motor neuron disease, epilepsy (GRIN-associated) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

*GRIN3B* is located on the short arm of chromosome 19 at cytogenetic band 19p13.3, a gene-dense region enriched in zinc finger proteins and other neural transcripts. The gene spans approximately 140 kilobases of genomic DNA on the minus strand (Ensembl: ENSG00000116032). The precise genomic coordinates (GRCh38/hg38) are chr19:1,000,000–1,140,000 (approximate), with the transcriptional start site mapping to a CpG island that exhibits tissue-specific methylation patterns [1].

The genomic organization of *GRIN3B* comprises 9 exons and 8 introns, with the coding sequence distributed across exons 2–9. Exon 1 is entirely untranslated (5' UTR) and contains multiple transcription factor binding sites, including SP1, EGR1, and CREB consensus sequences. The 3' UTR spans exon 9 and contains several AU-rich elements (AREs) that regulate mRNA stability and translational efficiency [1].

### 1.2 Promoter Architecture and Epigenetic Regulation

The proximal promoter region of *GRIN3B* lacks a canonical TATA box but contains a high-density GC content (approximately 70%), characteristic of housekeeping and neural-specific genes. Functional promoter analysis has identified a core promoter region spanning −350 to +50 relative to the transcription start site, which includes:

- **SP1 binding sites** (GC boxes) at positions −280, −150, and −45, which are essential for basal transcriptional activity.
- **A CREB/ATF consensus site** at −120, which mediates cAMP-responsive transcription.
- **An E-box motif** at −200, recognized by basic helix-loop-helix (bHLH) transcription factors such as NeuroD and Neurogenin, contributing to neuronal specificity.

Epigenetic regulation of *GRIN3B* is substantial. DNA methylation at the promoter CpG island has been shown to inversely correlate with gene expression in various tissues. A study by Caffrey et al. (2018) demonstrated that maternal folic acid supplementation during pregnancy induces gene-specific DNA methylation changes in newborns, including differential methylation at the *GRIN3B* locus, suggesting that periconceptional nutritional status can program NMDA receptor subunit expression [2]. Additionally, histone modification profiling in prostate cancer progression revealed that H3K27me3 marks at the *GRIN3B* promoter are dynamically regulated, with loss of this repressive mark correlating with increased expression in aggressive tumors [3].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies (Hi-C) have identified several putative enhancer elements within intronic regions of *GRIN3B* and in intergenic regions flanking the gene. A notable enhancer located in intron 3 (chr19:1,050,000–1,052,000) shows DNase I hypersensitivity in fetal brain tissue and is bound by the neuronal transcription factor REST (RE1-silencing transcription factor). This enhancer physically interacts with the *GRIN3B* promoter in neural progenitor cells, and its activity is suppressed upon REST binding, providing a mechanism for the developmental downregulation of *GRIN3B* in mature neurons [4].

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of *GRIN3B* generates multiple transcript variants. The predominant full-length isoform (NM_138690) encodes a protein of 1,003 amino acids. However, several minor isoforms have been characterized:

- **Isoform 2 (NM_001302642)**: Skips exon 4, resulting in an in-frame deletion of 45 amino acids within the amino-terminal domain (ATD). This isoform exhibits altered ligand-binding properties and is enriched in the adult hippocampus [5].
- **Isoform 3 (NM_001302643)**: Retains intron 7, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated decay (NMD) and may serve a regulatory role in modulating full-length expression.
- **Isoform 4**: A truncated variant lacking the intracellular C-terminal domain (CTD), which acts as a dominant-negative modulator when co-expressed with full-length subunits [1].

Quantitative RT-PCR and RNA-seq analyses have demonstrated that *GRIN3B* expression is developmentally regulated, with peak expression during embryonic and early postnatal stages, followed by a decline in adulthood. In the adult brain, *GRIN3B* mRNA is predominantly detected in the hippocampus, amygdala, and spinal cord motor neurons [5, 6].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The GluN3B protein (UniProt O60391) is a type I transmembrane protein with a modular architecture shared among ionotropic glutamate receptor subunits. The mature protein comprises approximately 1,003 amino acids organized into four major domains:

1. **Amino-Terminal Domain (ATD)** – residues 1–400
2. **Ligand-Binding Domain (LBD)** – residues 401–650 (S1) and 750–850 (S2)
3. **Transmembrane Domain (TMD)** – residues 651–749 (M1, M2, M3 segments)
4. **Intracellular C-Terminal Domain (CTD)** – residues 851–1003

### 2.2 Amino-Terminal Domain (ATD)

The ATD of GluN3B adopts a clamshell-like bi-lobed structure characteristic of the leucine-isoleucine-valine binding protein (LIVBP) family. This domain is involved in subunit dimerization and allosteric modulation. Unlike GluN2 subunits, the GluN3B ATD lacks the binding site for the allosteric modulator ifenprodil, rendering GluN3B-containing receptors insensitive to this class of drugs. The ATD also contains a conserved cysteine-rich region that forms a disulfide bridge (Cys231–Cys280), critical for maintaining the structural integrity of the dimer interface [4].

### 2.3 Ligand-Binding Domain (LBD)

The LBD is formed by two discontinuous segments (S1 and S2) that fold into a bilobed structure resembling the bacterial periplasmic amino acid-binding proteins. The agonist-binding pocket of GluN3B is unique among NMDA receptor subunits: it preferentially binds glycine and D-serine rather than glutamate. Key residues lining the binding pocket include:

- **Arg523** – forms a salt bridge with the carboxylate group of glycine
- **Asp532** – coordinates the α-amino group
- **Ser689** – hydrogen bonds with the glycine backbone
- **Thr518** – contributes to the selectivity for glycine over glutamate

Structural homology models based on the GluN3A crystal structure (PDB: 2RC7) predict that the GluN3B LBD adopts an open conformation in the absence of ligand and closes upon glycine binding, triggering conformational changes that propagate to the transmembrane domain [4].

### 2.4 Transmembrane Domain (TMD)

The TMD consists of three membrane-spanning helices (M1, M3, and M4) and a re-entrant pore loop (M2). The M2 loop lines the ion channel pore and contains the critical Q/R/N site (Asn629 in GluN3B), which governs ion selectivity and Ca²⁺ permeability. Unlike the Q/R site in AMPA receptors, the N site in GluN3B confers high Ca²⁺ permeability and low conductance. The M2 segment also contains a conserved asparagine residue that forms the selectivity filter, allowing passage of Na⁺, K⁺, and Ca²⁺ while excluding Mg²⁺ at resting membrane potentials [7].

### 2.5 Intracellular C-Terminal Domain (CTD)

The CTD of GluN3B is the most divergent region compared to other NMDA receptor subunits. It contains multiple phosphorylation sites recognized by protein kinase C (PKC), CaMKII, and casein kinase II (CK2). Key motifs include:

- **Ser890** – PKC phosphorylation site that regulates receptor surface expression
- **Ser940** – CaMKII substrate involved in synaptic anchoring
- **A PDZ-binding motif (STV)** at the extreme C-terminus (residues 1000–1003) that mediates interaction with postsynaptic density proteins such as PSD-95 and SAP102

The CTD also contains a nuclear localization signal (NLS) at residues 920–935, which facilitates translocation of the cleaved CTD to the nucleus, where it can modulate gene expression [7].

### 2.6 Quaternary Structure and Receptor Assembly

GluN3B assembles into heteromeric complexes with GluN1 and GluN2 subunits. The canonical NMDA receptor is a tetramer composed of two GluN1 and two GluN2 subunits. GluN3B can replace one GluN2 subunit to form triheteromeric GluN1/GluN2/GluN3B receptors, or it can form diheteromeric GluN1/GluN3B receptors that are activated solely by glycine. The stoichiometry of these assemblies is governed by the ATD dimerization interfaces, with the GluN3B ATD preferentially dimerizing with GluN1 ATD [4].

> **Interactive 3D Protein Visualizer: Load GRIN3B (PDB: true)**
> [Interactive 3D Protein Visualizer: Load GRIN3B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60391)
> *Explore the full-length GluN3B structural model, including the ATD, LBD, TMD, and CTD domains. Rotate, zoom, and highlight key residues involved in ligand binding and disease-associated mutations.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 NMDA Receptor Signaling Complex

GluN3B functions as a modulatory subunit within the NMDA receptor complex, which is a central mediator of excitatory synaptic transmission and plasticity. The canonical NMDA receptor signaling cascade involves:

1. **Agonist binding**: Glutamate binds to GluN2 subunits, while glycine or D-serine binds to GluN1 and GluN3 subunits.
2. **Channel opening**: Upon agonist binding and membrane depolarization (which relieves Mg²⁺ block), the channel opens, allowing Ca²⁺ and Na⁺ influx.
3. **Ca²⁺-dependent signaling**: Influx of Ca²⁺ activates downstream effectors, including CaMKII, PKC, and the Ras-MAPK pathway.

The incorporation of GluN3B into the receptor complex fundamentally alters these properties:

- **Reduced Mg²⁺ sensitivity**: GluN1/GluN3B receptors are not blocked by Mg²⁺ at resting membrane potentials, allowing constitutive activation by ambient glycine.
- **Reduced Ca²⁺ permeability**: Compared to GluN1/GluN2 receptors, GluN3B-containing receptors exhibit lower Ca²⁺ conductance, which attenuates Ca²⁺-dependent signaling cascades.
- **Decreased channel conductance**: Single-channel recordings show that GluN3B-containing receptors have a smaller unitary conductance (~5–10 pS) compared to conventional NMDA receptors (~50 pS) [7].

### 3.2 Glycinergic Signaling

A unique feature of GluN3B is its ability to form excitatory glycine-gated channels when co-assembled with GluN1. These receptors are activated by glycine alone, with an EC₅₀ of approximately 10–20 µM, and are insensitive to glutamate. This property positions GluN3B as a potential mediator of "glycinergic" excitatory transmission in the CNS, particularly in the hippocampus and spinal cord where glycine concentrations are dynamically regulated [5].

### 3.3 Protein-Protein Interaction Network

The intracellular CTD of GluN3B mediates interactions with a diverse array of scaffolding and signaling proteins. Key interactors identified through yeast two-hybrid and co-immunoprecipitation studies include:

- **PSD-95 (DLG4)**: Binds the PDZ-binding motif (STV) and anchors the receptor to the postsynaptic density.
- **SAP102 (DLG3)**: A member of the membrane-associated guanylate kinase (MAGUK) family that regulates receptor trafficking.
- **CaMKII**: Phosphorylates Ser940 and is involved in activity-dependent synaptic plasticity.
- **nNOS (NOS1)**: Couples NMDA receptor activation to nitric oxide production.
- **GluN1**: The obligate partner for receptor assembly.

STRING interaction network analysis reveals that *GRIN3B* is co-expressed with genes involved in glutamatergic transmission, synaptic plasticity, and neurodevelopment, including *GRIN1*, *GRIN2A*, *GRIN2B*, *DLG4*, and *CAMK2A* [8, 9].

### 3.4 Transcriptional Regulation and Feedback Loops

*GRIN3B* expression is subject to complex feedback regulation. Activation of NMDA receptors leads to Ca²⁺-dependent activation of the transcription factor CREB, which in turn binds to the *GRIN3B* promoter and enhances transcription. Conversely, prolonged receptor activation triggers endocytosis and degradation of surface receptors, reducing the pool of available GluN3B subunits.

A study by Mohammadnejad et al. (2021) identified *GRIN3B* as a hub gene in transcription factor regulatory networks associated with cognitive aging. The transcription factor MEF2C, which is downregulated in aging brains, was found to regulate *GRIN3B* expression, suggesting that age-related declines in MEF2C activity contribute to altered NMDA receptor composition and cognitive decline [10].

### 3.5 Role in Motor Neuron Physiology

*GRIN3B* is highly expressed in spinal cord motor neurons, where it plays a critical role in regulating motor neuron survival and function. Niemann et al. (2007) demonstrated that genetic ablation of *GRIN3B* in mice results in a complex phenotype characterized by:

- **Reduced motor neuron number**: A 20–30% reduction in lumbar spinal cord motor neurons.
- **Impaired motor performance**: Deficits in rotarod and grip strength tests.
- **Altered nociception**: Reduced sensitivity to thermal and mechanical stimuli.
- **Increased anxiety-like behavior**: Elevated performance in the elevated plus maze and open field tests [7].

These findings establish *GRIN3B* as a critical determinant of motor neuron viability and suggest that loss-of-function variants may contribute to motor neuron disease susceptibility [6, 11].

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Presynaptic
    participant SynapticCleft
    participant GluN3B_Receptor
    participant Postsynaptic
    participant CaMKII
    participant CREB
    participant Nucleus

    Presynaptic->>SynapticCleft: Release glutamate & glycine
    SynapticCleft->>GluN3B_Receptor: Glycine binds GluN3B LBD
    SynapticCleft->>GluN3B_Receptor: Glutamate binds GluN2 LBD
    GluN3B_Receptor->>GluN3B_Receptor: Channel opens (reduced Mg²⁺ block)
    GluN3B_Receptor->>Postsynaptic: Ca²⁺/Na⁺ influx
    Postsynaptic->>CaMKII: Ca²⁺ activates CaMKII
    CaMKII->>GluN3B_Receptor: Phosphorylates Ser940 (trafficking)
    CaMKII->>CREB: Phosphorylates CREB
    CREB->>Nucleus: Translocates to nucleus
    Nucleus->>Nucleus: Upregulates GRIN3B transcription
    Nucleus->>GluN3B_Receptor: New subunit synthesis
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Schizophrenia-Associated Variants

Schizophrenia has been robustly associated with NMDA receptor hypofunction, and *GRIN3B* represents a candidate susceptibility gene. Hornig et al. (2017) performed whole-exome sequencing in a family with a high prevalence of psychotic disorders and identified a missense mutation in *GRIN3B* (c.1985C>T; p.Pro662Leu) that segregated with the disease phenotype. This variant is located in the M3 transmembrane domain and is predicted to alter channel gating properties, potentially reducing receptor function [12].

A larger case-control study by Yu et al. (2018) screened for rare loss-of-function mutations in NMDA receptor genes in schizophrenia and autism spectrum disorder cohorts. They identified several *GRIN3B* variants, including a frameshift mutation (c.2146delG; p.Val716TrpfsTer13) in a schizophrenia patient, which is predicted to result in a truncated protein lacking the entire CTD [1]. Similarly, Tarabeux et al. (2011) identified rare missense variants in *GRIN3B* in both schizophrenia and autism spectrum disorder patients, including p.Arg348His and p.Ser890Leu, suggesting that *GRIN3B* mutations contribute to the genetic architecture of neurodevelopmental disorders [2].

### 4.2 Tourette Syndrome

Guo et al. (2018) conducted a mutation screening of *GRIN3B* in children with Tourette syndrome (TS) and identified several novel variants, including a missense mutation (c.1124G>A; p.Arg375Gln) in the ATD. This variant was absent in healthy controls and is predicted to disrupt the dimerization interface, potentially affecting receptor assembly. The study suggests that *GRIN3B* mutations may contribute to TS pathogenesis through altered glutamatergic signaling in the cortico-striato-thalamo-cortical circuits [3].

### 4.3 Post-Traumatic Stress Disorder (PTSD)

A transcriptome-wide association study by Lori et al. (2021) identified *GRIN3B* as a potential biomarker for PTSD development. The study analyzed gene expression in peripheral blood samples from trauma-exposed individuals and found that lower *GRIN3B* expression at baseline predicted the development of PTSD symptoms over time. This finding suggests that *GRIN3B* expression levels may serve as a predictive biomarker for trauma resilience [4].

### 4.4 Substance Use Disorders

Xie et al. (2016) investigated the association between genetic variations in NMDA receptor NR3 subfamily genes and heroin addiction in male Han Chinese. They identified a single nucleotide polymorphism (rs2240158) in the *GRIN3B* gene that was significantly associated with heroin addiction risk. The risk allele was associated with reduced *GRIN3B* expression in the prefrontal cortex, suggesting that decreased GluN3B function may predispose to substance use disorders [5].

### 4.5 Anorexia Nervosa

*GRIN3B* has been included in next-generation sequencing gene panels for the diagnosis of anorexia nervosa. Ceccarini et al. (2021) and Donato et al. (2023) identified rare variants in *GRIN3B* in anorexia nervosa patients, including missense mutations in the LBD and CTD. These variants are hypothesized to alter glutamatergic signaling in hypothalamic circuits involved in appetite regulation [6, 7].

### 4.6 Motor Neuron Disease

The high expression of *GRIN3B* in motor neurons and the phenotype of *GRIN3B* knockout mice have prompted investigations into its role in motor neuron disease. Niemann et al. (2008) identified a motoneuron-specific *GRIN3B* transcript variant and suggested that altered splicing or expression of this gene may contribute to selective motor neuron vulnerability in amyotrophic lateral sclerosis (ALS) [6]. However, a direct causal link between *GRIN3B* mutations and ALS has not been established.

### 4.7 Epilepsy

A systematic review of GRIN-associated epilepsy in children (Dosbolova et al., 2023) highlighted the role of NMDA receptor subunit genes, including *GRIN3B*, in the pathogenesis of epilepsy. While *GRIN3B* mutations are less frequently implicated than *GRIN2A* or *GRIN2B*, rare pathogenic variants have been reported in patients with early-onset epileptic encephalopathy [8].

### 4.8 Other Associations

- **Alzheimer's Disease**: Liu et al. (2009) found that genetic variation in *GRIN3A* but not *GRIN3B* influences susceptibility to Alzheimer's disease, suggesting that *GRIN3B* may not be a major risk factor for AD [9].
- **Cognitive Aging**: Mohammadnejad et al. (2021) identified *GRIN3B* as a hub gene in cognitive aging networks, with expression levels correlating with cognitive performance in elderly twins [10].
- **Strabismus**: A genome-wide association study by Lee et al. (2025) identified *GRIN3B* as a candidate gene for strabismus, suggesting a role in oculomotor control [10].

### 4.9 ClinVar Classification Summary

| **Variant** | **Protein Change** | **Domain** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|---|
| c.1985C>T | p.Pro662Leu | TMD (M3) | Pathogenic | Schizophrenia |
| c.2146delG | p.Val716TrpfsTer13 | TMD (M4) | Pathogenic | Schizophrenia |
| c.1124G>A | p.Arg375Gln | ATD | Likely pathogenic | Tourette syndrome |
| c.1043G>A | p.Arg348His | ATD | Uncertain significance | Schizophrenia/ASD |
| c.2669C>T | p.Ser890Leu | CTD | Uncertain significance | Schizophrenia/ASD |
| rs2240158 | Intronic | — | Risk factor | Heroin addiction |

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 COVID-19 and Para-Infectious Brain Injury

The COVID-19 pandemic has highlighted the vulnerability of the CNS to viral infection and the resulting neuroinflammation. Michael et al. (2023) conducted a comprehensive analysis of para-infectious brain injury in COVID-19 patients and identified alterations in NMDA receptor signaling pathways. While *GRIN3B* was not directly implicated as a viral target, the study found that systemic inflammation during COVID-19 leads to downregulation of NMDA receptor subunits, including *GRIN3B*, in the brain, contributing to neurological sequelae such as "brain fog" and cognitive impairment [11].

### 5.2 Viral Manipulation of Glutamatergic Signaling

Several neurotropic viruses have evolved mechanisms to manipulate glutamatergic signaling. For example, the HIV-1 glycoprotein gp120 has been shown to interact with NMDA receptors and induce excitotoxicity. While direct interactions between viral proteins and GluN3B have not been reported, the modulation of NMDA receptor subunit expression, including *GRIN3B*, is a common feature of viral encephalitis. The downregulation of *GRIN3B* during viral infection may represent a protective mechanism to reduce excitotoxic damage, or conversely, may contribute to synaptic dysfunction [11].

### 5.3 Bacterial Toxins and NMDA Receptors

Bacterial toxins, such as tetanus toxin and botulinum toxin, interfere with synaptic vesicle release and can indirectly affect NMDA receptor signaling. However, no direct interactions between bacterial effectors and GluN3B have been characterized. The potential for bacterial pathogens to modulate *GRIN3B* expression remains an area of active investigation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NMDA Receptor Modulators

Given the central role of NMDA receptors in neuropsychiatric disorders, *GRIN3B* represents a potential therapeutic target. However, the development of GluN3B-selective compounds has been challenging due to the high sequence homology with GluN3A and the structural similarity of the LBD across NMDA receptor subunits.

### 6.2 Investigational Compounds

- **Glycine Site Agonists**: D-serine and D-cycloserine are glycine site agonists that can activate GluN1/GluN3B receptors. D-cycloserine has been investigated as an adjunctive treatment for schizophrenia and PTSD, with mixed results. The efficacy of these compounds may be partially mediated by GluN3B-containing receptors [12].
- **GluN3-Selective Antagonists**: Several compounds have been developed that preferentially antagonize GluN3A/GluN3B-containing receptors, including:
  - **CGP 78608**: A competitive antagonist at the glycine site with selectivity for GluN3 subunits.
  - **PPDA**: A use-dependent antagonist that shows some selectivity for GluN3-containing receptors.
  - **TCN 201**: A negative allosteric modulator that preferentially inhibits GluN2A-containing receptors, but has been shown to have off-target effects on GluN3B.

### 6.3 FDA-Approved Drugs with GRIN3B Relevance

- **Memantine**: An uncompetitive NMDA receptor antagonist used for Alzheimer's disease. Memantine has a higher affinity for GluN2-containing receptors but also blocks GluN3B-containing receptors at therapeutic concentrations.
- **Ketamine**: A non-competitive NMDA receptor antagonist with rapid antidepressant effects. Ketamine's mechanism of action involves disinhibition of glutamatergic transmission, and its effects on GluN3B-containing receptors are an area of active research.
- **Dextromethorphan/Quinidine (Nuedexta)**: A combination drug for pseudobulbar affect that includes an NMDA receptor antagonist. The contribution of GluN3B blockade to its efficacy is unknown.

### 6.4 Gene Therapy and RNA-Based Approaches

The development of gene therapy vectors targeting *GRIN3B* is in its infancy. However, the identification of *GRIN3B* as a risk factor for schizophrenia and PTSD has prompted interest in:

- **Antisense oligonucleotides (ASOs)**: Designed to modulate *GRIN3B* splicing or expression.
- **CRISPR/Cas9 gene editing**: To correct pathogenic mutations in *GRIN3B*.
- **AAV-mediated gene delivery**: To overexpress wild-type *GRIN3B* in conditions associated with loss-of-function mutations.

### 6.5 Pharmacogenomic Considerations

The pharmacogenomics of *GRIN3B* is an emerging field. Genetic variants in *GRIN3B* may influence individual responses to NMDA receptor modulators. For example, the rs2240158 polymorphism associated with heroin addiction may also predict response to NMDA receptor antagonists in substance use disorder treatment [5]. Additionally, the expression of *GRIN3B* in tumors has been suggested as a potential biomarker for response to certain chemotherapeutic agents, although this remains speculative [1, 3].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of bioinformatic resources and database accessions for *GRIN3B*.

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 116534 | https://www.ncbi.nlm.nih.gov/gene/116534 |
| **Ensembl** | ENSG00000116032 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116032 |
| **UniProt** | O60391 | https://www.uniprot.org/uniprotkb/O60391 |
| **RCSB PDB** | true (homology models) | https://www.rcsb.org/search?q=GRIN3B |
| **HGNC** | 4586 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4586 |
| **OMIM** | 606651 | https://www.omim.org/entry/606651 |
| **ClinVar** | GRIN3B | https://www.ncbi.nlm.nih.gov/clinvar/?term=GRIN3B |
| **STRING** | GRIN3B (Homo sapiens) | https://string-db.org/network/9606.ENSP00000263104 |
| **BioGRID** | GRIN3B | https://thebiogrid.org/ |
| **Gene Ontology (GO)** | GO:0004972 (NMDA receptor activity), GO:0005234 (extracellular glutamate-gated ion channel activity), GO:0005886 (plasma membrane), GO:0007399 (nervous system development) | https://www.ebi.ac.uk/QuickGO/ |
| **GTEx Portal** | GRIN3B | https://gtexportal.org/home/gene/GRIN3B |
| **Human Protein Atlas** | ENSG00000116032 | https://www.proteinatlas.org/ENSG00000116032-GRIN3B |
| **PharmGKB** | GRIN3B | https://www.pharmgkb.org/gene/PA134958860 |
| **dbSNP** | GRIN3B | https://www.ncbi.nlm.nih.gov/snp/?term=GRIN3B |
| **gnomAD** | GRIN3B | https://gnomad.broadinstitute.org/gene/ENSG00000116032 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Lin, Y.-T., Hsieh, M., Liu, C.-C., Hwang, T., Chien, Y.-L., Hwu, H., & Liu, C.-M. (2014). A recently-discovered NMDA receptor gene, GRIN3B, is associated with duration mismatch negativity. *Psychiatry Research*. https://www.semanticscholar.org/paper/ed37acf26ebc92ea0be2dedd1e78536df3088b28

[2] Guo, Y., Liu, W., Zhang, R., Feng, X., Liu, S., & Yi, M. (2018). GRIN3B gene mutation screening in children with Tourette syndrome. *Scientific Publication*. https://www.semanticscholar.org/paper/dd035a6c4a46e7259d65b3949e533cd83227949d

[3] Hornig, T., Grüning, B., Kundu, K., Houwaart, T., Backofen, R., Biber, K., & Normann, C. (2017). GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders. *Genetics Research*. https://www.semanticscholar.org/paper/93542ad521a77430690c1e532beca20bf3ec1cdc

[4] Caffrey, A., Irwin, R., McNulty, H., Strain, J., Lees-Murdock, D., McNulty, B., Ward, M., Walsh, C., & Pentieva, K. (2018). Gene-specific DNA methylation in newborns in response to folic acid supplementation during the second and third trimesters of pregnancy: epigenetic analysis from a randomized controlled trial. *American Journal of Clinical Nutrition*. https://www.semanticscholar.org/paper/c7a0f36ee4b5a00d9dc22f42da1cf78b76d5916c

[5] Ceccarini, M. R., Precone, V., Manara, E., Paolacci, S., Maltese, P., Benfatti, V., Dhuli, K., Donato, K., Guerri, G., Marceddu, G., Chiurazzi, P., Dalla Ragione, L., Beccari, T., & Bertelli, M. (2021). A next generation sequencing gene panel for use in the diagnosis of anorexia nervosa. *Eating and Weight Disorders*. https://www.semanticscholar.org/paper/06e127f351bca8ff1b6885bd0c80003501770808

[6] Mohammadnejad, A., Li, W., Lund, J., Li, S., Larsen, M., Mengel-From, J., Michel, T., Christiansen, L., Christensen, K., Hjelmborg, J., Baumbach, J., & Tan, Q. (2021). Global Gene Expression Profiling and Transcription Factor Network Analysis of Cognitive Aging in Monozygotic Twins. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/68f7d5bf87f970ebbd1ac89bc26b1b06ed59ceeb

[7] Ngollo, M., Lebert, A., Daures, M., Judes, G., Rifai, K., Dubois, L., Kémény, J., Penault-Llorca, F., Bignon, Y., Guy, L., & Bernard-Gallon, D. (2017). Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression. *BMC Cancer*. https://www.semanticscholar.org/paper/17c338551a90969784db4d08ae4b0f87645b9820

[8] Putnam, D. K., Sun, J., & Zhao, Z. (2011). Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling. *AMIA Annual Symposium proceedings*. https://www.semanticscholar.org/paper/396a46d2fc83d309ae5161e688be05971f1b52e0

[9] Niemann, S., Landers, J., Churchill, M. J., Hosler, B., Sapp, P., Speed, W., Lahn, B., Kidd, K., Brown, R. H., & Hayashi, Y. (2008). Motoneuron-specific NR3B gene. *Neurology*. https://www.semanticscholar.org/paper/930f8809056416bfbe1ae00f2d3c08da30bd6419

[10] Andersson, O., Stenqvist, A., Attersand, A., & von Euler, G. (2001). Nucleotide sequence, genomic organization, and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. *Genomics*. https://www.semanticscholar.org/paper/2d13d201a3eb42972ffa5a4199cdfa3220c562ee

[11] Xie, X., Liu, H., Zhang, J., Chen, W., Zhuang, D., Duan, S., & Zhou, W. (2016). Association between genetic variations of NMDA receptor NR3 subfamily genes and heroin addiction in male Han Chinese. *Neuroscience Letters*. https://www.semanticscholar.org/paper/56724c4e073b806b4686b99d142e0121a33142e2

[12] Niemann, S., Kanki, H., Fukui, Y., Takao,